Pegylated niosomal nanoparticles loaded with vincristine: Characterization and in vitro evaluation

Purpose: To investigate the effect of pegylated niosomal vincristine (VCR) on enhanced performance, drug resistance and prolonged blood circulation time.Methods: Pegylated niosomal VCR was synthesized by reverse phase evaporation. The mean diameter, size distribution, and zeta potential of pegylated niosomal VCR were evaluated using a Zetasizer. The half-maximal concentration (IC50) values of pegylated niosomal VCR and standard VCR were determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The impact of pegylated niosomal VCR on apoptosis and cell cycle of BCL1 lymphoma cancer cells were investigated.Results: The mean diameter, size distribution and zeta potential of pegylated niosomal VCR were 220 nm, 0.4, and –18.8 mV, respectively. Cell proliferation was evaluated using the MTT assay. The IC50 values of pegylated niosomal VCR and standard VCR were 1.6 and 3.5 μg/mL, respectively, after a 24-h incubation. The cytotoxicity of pegylated niosomal VCR was twice that of standard VCR. Furthermore, flow cytometric analysis of the cell cycle showed that pegylated niosomal VCR induced greater mitotic arrest than did standard VCR.Conclusions: The findings demonstrate the effective antitumor activity of pegylated niosomal VCR compared with standard VCR.Keywords: Niosome, Anti-tumour, Polyethylene glycol, Vincristine,   Encapsulation, Lymphom

Datasets of a novel bivalent single chain antibody constructed by overlapping oligonucleotide annealing method targeting human CD123

Current therapies for acute myeloid leukemia (AML), are associated with high relapse rates. Hence, development of new therapeutic strategies is crucial to circumvent this problem. Bivalent antibody technology has been used to engineer novel antibody fragments with increased avidity, by assembling two scFv in a single molecule. Here, we present accompanying data from construction and characterization experiments of a biscFv antibody targeting CD123, the most important biomarker of leukemic cancer stem cells which play a key role in relapsed AML after chemotherapy. Data in this article are related to the research paper “Development of a novel engineered antibody targeting human CD123” Moradi-Kalbolandi S. et al. (2016) [1]